Revagenix leverages a small team to deliver results equivalent to a company several times our size. Through a world-class network of strategic collaborators, partners, investors, and advisors we’ve created a meta-team capable of delivering the next generation of antibiotics.

Ryan Cirz, PhD

CEO

Andrew McCandlish, PhD

COO

Andrew Calabrese, PhD

Chemistry and Intellectual Property

David Thatcher

Consulting CFO, Engine Room

Tina Larson

Board Chair

President & COO, Recursion

Aleks Engel, PhD

Partner, Novo Holdings

Andrew Calabrese, PhD

Co-founder

Venture Partner, Anterra Capital and Scientific Co-Founder, Animol Discovery

Ryan Cirz, PhD

Co-founder & CEO

Andrew McCandlish, PhD

Co-founder & COO

Bruce Montgomery, MD

Board Observer

CEO, Avalyn Pharma

Lloyd Czaplewski

CSO, Persica Pharmaceuticals

Director, Chemical Biology Ventures

Chair, Novo Repair Impact Scientific Selection Board

Ian Friedland, MD

Strategic Consultant, Medical and Development

Tina Larson

President & COO, Recursion

Bruce Montgomery, MD

CEO, Avalyn Pharma

Heinz Moser, PhD

Executive Director, Global Discovery Chemistry, Novartis Institutes for Biomedical Research

Novo Holdings

National Institute of Allergy and Infectious Diseases (NIAID)